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1 Abstract 
Myelodysplastic syndromes (MDS) are common hematopoietic disorders that are 
associated with bone marrow failure and the possibility of developing leukemia (1). 
MDS cells often contain chromosomal abnormalities, which significantly impact on 
the prognosis of the disease as documented by the contribution of chromosomal 
aberrations to the International Prognostic Scoring System (IPSS) used to 
prognostically classify MDS cases. Our understanding of the molecular mechanism 
of MDS has been increasing especially due to the advancements in genomics and 
next generation sequencing. An increasing list of mutated genes is being described 
in MDS including hematopoietic transcription factors (ETV6, CEBPA, RUNX1, SPI1 
(PU.1)) (2-5), epigenetic regulators (ASXL1, TET2, DNMT3A, IDH1, IDH2, EZH2, 
SUZ12) (3, 6, 7) and microRNAs (8, 9), RNA splicing factors (SF3B1, SRSF2, 
U2AF1, ZRSR2) (10), cell cycle regulators (CDKN1A,TP53,BCL2, AURKA, AURKB, 
CDC20, MAD2L1, TUBG1) (10-14), members of the cohesin complex (STAG2, 
RAD21, SMC1, SMC3A) (10, 15, 16), members of other signaling pathways (JAK2, 
IRAK1, CTNNB1, NOTCH1, NPM1, SMAD7, TGFB1, NF-κB) (9, 16-20), proteins 
involved in immunological processes (TLR2, STAT3) (21, 22), and others factors 
(CBL, CALR, BCOR, BCORL1, SETBP1, GNAS, CDKN2B, Nup98, HoxD13) (2, 3, 
10, 23-25). Identification of mutations in these genes has increased our 
understanding of the disease but there is a lot to be done in order to gain insights 
into the mechanisms of MDS pathogenesis. Mutations in the members of the cohesin 
complex including RAD21 and STAG2 have been found in MDS and other types of 
cancer such as bladder (26-28), breast (29), and colorectal cancer (30). These 
mutations are associated with chromosomal instability and aneuploidy in some 
cancer types such as bladder cancer (31) but this finding remains controversial in 
other cancer types (32) and requires further mechanistic studies and patient data 
analysis in order to be validated. Genome engineering has been improved greatly 
over the past couple of years with the recent introduction of the CRISPR/Cas9 
system by the Zhang group (33), making functional validation of the genomic data 
obtained from massively parallel sequencing studies feasible. 
In this study, we characterized a panel of 63 genes that has been reported to be 
frequently mutated in MDS, in 90 patient samples from MDS patients with and 
without chromosomal aberrations in their bone marrow mononuclear cells using a 
targeted re-sequencing approach to assess the frequency of mutations in these 
genes. This approach allowed us to determine whether the mutation spectrum is 
different in MDS cases with and without chromosomal aberrations, especially with 
regard to the occurrence of cohesin complex subunit mutations. In addition, we 
functionally characterized the cohesin complex subunit STAG2 that has been 
reported to be mutated in several cancers including MDS and reported to be 
 9 
associated with chromosomal instability at least in some studies. To do this, we used 
CRISPR/Cas9 genome engineering to knock out this gene and analyzed for signs of 
chromosomal instability. We have used HCT116-p53+/+ and HCT116-p53-/- cell lines 
for these functional analyses. Finally, we also analyzed the expression of STAG2 in 
AML samples using immunofluorescence microscopy and Western blotting. 
TP53 somatic SNVs were found in 7/90 (7.8%) of the cases and were mainly 
associated with complex karyotypes, which is in accordance with previous reports. 
STAG2 was mutated in only 4/90 (4.4%) of samples. No mutations in other cohesin 
components were found. On the other hand, STAG2 expression was lost in 18 out of 
74 (24.3%) AML samples due to STAG2 mutations in 20% (2/10) and promoter 
methylation in 58.3% (7/12) of cases. In addition, we used CRISPR/Cas9 genome 
editing to knock out STAG2 in diploid, chromosomally stable HCT116-p53+/+ and 
HCT116-p53-/- cells. Whereas loss of STAG2 led to alterations in gene expression 
profiles in both cell lines, chromosome aberrations were only induced in the 
HCT116-p53-/- background. We conclude that the expression of STAG2 is lost in 
about one quarter of AML cases, frequently as a consequence of promoter 
methylation. Depending on the genetic background, both disturbed gene expression 
and chromosomal aberrations are associated with loss of STAG2. 
 
 
 
2 Zusammenfassung  
 
Myelodysplastische Syndrome (MDS) sind hämatopoetische Erkrankungen, die auf 
Knochenmarksfehlfunktionen zurückzuführen sind und zu einer Leukämie führen 
können. MDS-Zellen weisen häufig chromosomale Aberrationen auf, die einen 
erheblichen Einfluss auf die Krankheitsprognose haben. Dies wird durch das 
International Prognostic Scoring System (IPSS) deutlich, welches die MDS-Klassen 
anhand chromosomaler Aberrationen prognostisch einteilt. Unser Verständnis des 
molekularen Mechanismus von MDS hat vor allem aufgrund der Fortschritte in 
Mutationsanalyse mittels Next Generation Sequenzierung (NGS) zugenommen. Eine 
wachsende Liste von mutierten Genen sind in MDS beschrieben, darzu gehören 
hämatopoetische Transkriptionsfaktoren (ETV6, CEBPA, RUNX1, SPI1, PU.1), 
epigenetische Regulatoren (ASXL1, TET2, DNMT3A, IDH1, IDH2, EZH2, SUZ12), 
microRNAs, RNA-Splicing Faktoren (SF3B1, SRSF2, U2AF1, ZRSR2), Zellzyklus-
Regulatoren (CDKN1A, TP53, BCL2, AURKA, AURKB, CDC20, MAD2L1, TUBG1), 
Mitglieder des Cohesin-Komplexes (STAG2, RAD21, SMC1, SMC3A), Mitglieder 
anderer Signalwege (JAK2, IRAK1, CTNNB1, NOTCH1, NPM1, SMAD7, TGFB1, 
NF-
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(CBL, CALR, BCOR, BCORL1, SETBP1, GNAS, CDKN2B, Nup98, HoxD13). Die 
Identifikation dieser Genmutationen hat unser Verständnis der Krankheit verbessert, 
aber es gibt noch einiges zu tun, um einen detaillierteren Einblick in den 
Mechanismus der MDS-Pathogenese zu gewinnen. Mutationen in Mitgliedern des 
Cohesin-Komplexes wie RAD21 und STAG2 wurden in MDS und in anderen 
Krebsarten wie Blasen-, Brust- und Darmkrebs gefunden. Diese Mutationen werden 
in einigen Krebsarten wie Blasenkrebs mit chromosomaler Instabilität und 
Aneuplodie in Verbindung gebracht, während bei anderen Krebsarten diese 
Hypothese umstritten ist und weiterer mechanistischer Untersuchungen und 
Analysen von Patientendaten bedarf. In den letzten Jahren hat sich das Genome-
Engineering durch die Einführung der CRISPR/Cas9-Technologie durch die Zhang-
Gruppe stark verbessert, wodurch eine funktionelle Validierung von genomischen 
Datensätzen aus Sequenzierungsstudien praktikabel wurde. 
In der vorliegenden Arbeit haben wir 90 Proben von MDS-Patienten mit oder ohne 
chromosomale Aberrationen in mononukleären Zellen des Knochenmarkes einer 
gezielten Re-Sequenzierungsanalyse unterzogen. Dabei analysierten wir eine 
Gruppe von 63 Genen, welche häufig beim MDS mutiert vorliegen, und bewerteten 
die Häufigkeiten der nachgewiesenen Genmutationen.  Dieser Ansatz ermöglichte 
die Untersuchung des Mutationsspektrums in Hinblick auf Unterschiede zwischen 
MDS-Fällen mit und ohne chromosomale Aberrationen, wobei wir vor allem an 
Mutationen in Komponenten des Cohesin-Komplexes interessiert waren. Zusätzlich 
charakterisierten wir die Cohesin-Komplex-Untereinheit STAG2 funktionell. STAG2 
ist in mehreren Krebsarten darunter MDS mutiert und wird zumindest in einigen 
Studien mit chromosomaler Instabilität in Verbindung gebracht. Zur funktionellen 
Charakterisierung schalteten wir STAG2 in den diploiden, chromosomal stabilen 
Zelllinien HCT116-p53+/+ und HCT116-p53-/- mit Hilfe der CRISPR/Cas9 Genome 
Engineering Technologie aus, und untersuchten den Grad der chromosomalen 
Instabilität. Außerdem analysierten wir mittels Immunfluoreszenzmikroskopie und 
Western Blot-Analysen die STAG2-Expression in mehreren AML-Patientenproben. 
Somatische SNVs in TP53 wurden in sieben der 90 MDS-Patientenproben (7.8%) 
gefunden, wobei diese Proben häufig einen komplexen Karyotyp aufwiesen; dies 
stimmt mit früheren Studien überein. STAG2 war nur in vier der 90 Proben (4.4%) 
mutiert, während wir in den anderen Cohesin-Komplex-Komponenten keine 
Mutationen detektieren konnten. Auf der anderen Seite konnten wir keine STAG2-
Expression in 18 der 74 AML-Patientenproben (24.3%) beobachten, was auf 
STAG2-Mutationen (2/10; 20%) oder STAG2-Promotormethylierungen (7/12; 58.3%) 
zurückgeführt werden konnte. Der Verlust der STAG2-Expression in den beiden 
Zelllinien HCT116-p53+/+ und HCT116-p53-/- führte zu veränderten 
Genexpressionsprofilen in beiden Zelllinien, während chromosomale Aberrationen 
nur in den STAG2-deletierten HCT116-p53-/-  induziert wurden. 
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3 Introduction 
3.1 Normal hematopoiesis  
Blood is composed of blood cells and plasma. Blood cellular components are 
differentiated from hematopoietic stem cells (HSCs) during hematopoiesis. HSCs are 
multipotent stem cells that are able to undergo self-renewal and differentiate into all 
blood cell lineages. Hematopoiesis occurs for the first time in human fetus at about 
on month of age in the yolk sac in the forms of blood islands. During prenatal 
development, hematopoiesis occurs also in the liver, spleen and lymph nodes. From 
about month four in human fetus, hematopoiesis starts in the bone marrow which is 
the only postnatal place for hematopoiesis however, maturation of lymphoid cells 
occurs in secondary lymphoid organs. hematopoiesis occurs mainly in tibia and 
femur till the age of about 30 years after the age of 30 it exclusively occurs in the 
vertebral and pelvis, sternum and ribs (34) (Figure 1).  
 
 
 
Figure 1: Hematopoiesis sites during development 
Hematopoiesis starts in one month old embryos in the yolk sac and continues in liver, spleen and 
bone marrow. At birth hematopoiesis becomes limited to the bone marrow as indicated. Figure taken 
from wikipedia 
 
HSCs differentiate into common myeloid progenitors (CMP) and common lymphoid 
progenitors (CLPs). CMPs produce all myeloid lineage cells including thrombocytes, 
erythrocytes, monocytes, basophils, neutrophils, and eosinophils. CLPs differentiate 
into B- and T-lymphocytes. Each differentiation step is tightly regulated and 
dependent on different growth factors and cytokines (Figure 2). The 
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microenvironment in bone marrow in which HSCs reside is called niche which 
includes all the cells and the factors that affect self-renewal and differentiation of 
HSCs. Changes in the niche or mutations in cytokines and growth factors or HSC 
genes can result in malignant hematopoiesis. 
 
Figure 2: Differentiation of hematopoietic stem cells  
Multipotent hematopoietic stem cells differentiate into common lymphoid progenitors, which produce 
all lymphocytes upon differentiation, and common myeloid progenitors which further differentiate into 
all myeloid lineage cells. Different growth factors for each differentiation step are shown. SCF, Stem 
Cell Factor; TPO, Thrombopoietin; IL, Interleukin; GM-CSF, Granulocyte Macrophage-Colony 
Stimulating Factor; EPO, Erythropoietin; M-CSF, Macrophage-Colony Stimulating Factor; G-CSF, 
Granulocyte-Colony Stimulating Factor; SDF-1, Stromal cell-derived factor-1; FLT-3 ligand, FMS-like 
tyrosine kinase 3 ligand; TNF- , Tumour necrosis factor-alpha; TGFβ, Transforming growth factor 
beta. Figure taken from wikipedia 
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3.2 Malignant hematopoiesis 
 
Hematopoiesis is a sophisticated process that is tightly controlled at different steps 
during differentiation. Malignant hematopoiesis can occur due to any change in the 
normal hematopoiesis process. For instance, any mutation in the growth factors 
regulating different steps of hematopoiesis can lead to malignant hematopoiesis. It is 
not clear whether malignant hematopoiesis occurs in HSCs or in other cells during 
differentiation. According to the literature, there are two main scenarios: it can either 
occur in the common myeloid progenitors in the myeloid lineage or in the common 
lymphoid progenitors in the lymphoid lineage. In general, myeloid malignancies are 
known as leukemias and lymphoid malignancies are called lymphomas. Malignant 
hematopoiesis is also categorized into acute and chronic malignancies based on the 
clinical course of the disorders. Myeloid malignancies include acute myeloid 
leukemia (AML) and chronic myeloid malignancies. Myelodysplastic syndrome 
(MDS) is a chronic myeloid malignancy which in 30% of the cases leads to 
secondary AML (3). 
 
3.3 Myelodysplastic syndromes (MDS) 
3.3.1 MDS 
MDS are clonal myeloid disorders in which abnormal blood cells are produced in the 
bone marrow mainly as a result of mutations in genes regulating the stem cell fate. 
Infection, anemia, shortness of breath, fatigue or bleeding may occur as a result of 
MDS especially in the late phases of the disease. About 30% of MDS transform into 
AML. MDS occurs rarely below the age of 50 but is common in more than 70 years 
old patients. MDS occurs annually in more than 20 per 100,000 people (35). The 
overall survival rate is on average about 2.5 years from initial diagnosis. Like other 
types of cancer, the risk factors for MDS are not quite clear but exposure to 
chemotherapy and radiation are among them. Cytopenias including anemia are 
common in MDS, which are first identified in routine blood cell counts as the first step 
in the diagnosis of MDS. The next step in the diagnosis of MDS is usually looking at 
blood and bone marrow smears, which reveal the typical morphologic characteristics 
of MDS. Bone marrow dysplasia, dimorphic red blood cells, and ring sideroblasts are 
among the common morphologic features of MDS (1). Karyotyping of the bone 
marrow cells using conventional cytogenetic methods and fluorescence in situ 
hybridization (FISH) is the next step in the diagnosis of MDS, which is used for 
further classification. Nowadays, sequencing of a panel of about 50 genes that are 
recurrently mutated in MDS based on next generation sequencing studies has 
become part of the diagnosis in some centers. However, the clinical outcomes 
associated with these mutations are still mainly unknown and need to be further 
studied. 
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3.3.2 MDS classification 
MDS pathogenesis includes cytopenias, morphological and cytogenetic 
abnormalities, genetic and epigenetic dysregulation, and a deregulated immune 
system. Since the pathogenesis of MDS is complicated, it is difficult to classify MDS 
like other myeloid malignancies (36). There are different classification systems which 
use a different set of criteria for MDS classification. However, percentage of blasts in 
bone marrow, cytopenia, dysplasia, and more recently cytogenetics are the main 
criteria for MDS classification. MDS are highly heterogeneous disorders regarding 
karyotype. 30 to 80% of patients have chromosomal abnormalities while the 
remaining 20 to 70 percent have a normal karyotype. Chromosomal abnormalities 
occur as a single abnormality, in combination with another abnormality, or together 
with two or more other abnormalities (complex karyotype). Deletion (5q) is the most 
frequent chromosomal abnormality either alone or in combination with other 
abnormalities. Figure 3 represents the karyotype abnormalities in 1080 MDS 
patients (36).  
 
 
Figure 3: Representative karyotype abnormalities in MDS 
Frequency distribution of chromosome abnormalities in 1080 patients with MDS. Taken from (37)        
. 
 
 16 
The most up to date system for putting chromosomal abnormalities in MDS into 
prognostic categories is the so-called revised international prognostic system (IPSS-
R) which classifies chromosomal abnormalities in five prognostic subcategories: very 
good (-Y, del(11q)), good (normal, del (5q), del (12p), del(20q), double including del 
(5q)), intermediate (del(7q), +8, +19, i(17q), or any other single or double clones), 
poor (-7, inv(3)/t(3q)/del(3q), double including -7/del(7q), complex: 3 abnormalities), 
and very poor (complex: > 3 abnormalities) (45)  (Table 1). 
 
Table 1: IPSS-R MDS cytogenetic scoring system 
Taken from (42). 
 
There are four major systems for MDS classification: the French-American-British 
(FAB) system(1, 38), the world health organization system (WHO)(39, 40), the 
international prognostic scoring system (IPSS), and the revised international 
prognostic scoring system (IPSS-R). FAB being the oldest system and IPSS-R is the 
most up to date system. Each system uses a different set of criteria for classifying 
MDS. However, percentage of blasts in bone marrow, cytopenia, dysplasia, and 
more recently cytogenetics are the main criteria for MDS classification. For the 
purpose of the current introduction the IPSS and IPSS-R systems will be explained 
below.     
In 1997 a group of scientists came together in a workshop in order to generate an 
international prognostic scoring system (IPSS) for MDS. The IPSS was supposed to 
be more precise than other classification systems in terms of prognostic power and 
clinical outcomes. The IPSS uses three criteria to classify MDS patients: the bone 
marrow blast percentage, the number of cytopenias, and the cytogenetics. The first 
two criteria are the same as in the FAB system. However, the IPSS puts the 
cytogenetic abnormalities into prognostic categories for the first time which is quit 
challenging due to the fact that chromosomal abnormalities are highly 
heterogeneous and they occur either alone or in combination with two or more other 
abnormalities. The IPSS puts the cytogenetic abnormalities into three groups good 
(normal karyotype, isolated del(5q), del(20q) and loss of the Y-chromosome), poor 
(any chromosome 7-abnormality, complex ( ≥ 3 cytogenetic changes)) and 
intermediate (any other abnormality) (41). Using the risk score for bone marrow 
blasts, number of cytopenias and the cytogenetic subcategory, the IPSS puts MDS 
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paitients into 4 risk groups in terms of overall survival and AML evolution: low, 0; 
intermediate-1 (INT-1), 0.5 to 1.0; intermediate-2 (INT-2), 1.5 to 2.0; and high, ≥2.5 
Table 2. 
   
Table 2: IPSS for MDS 
Taken from (41) 
 
The four major IPSS groups were clearly distinct in terms of survival and AML 
evolution which shows the reliability of IPSS classification system Figure 4.  
 
 
Figure 4: Age-related survival and AML evolution of MDS patients  
Survival (A) and AML evolution (B) of MDS patients related to their classification by the IPSS for MDS: 
Low, INT-1, INT-2, and High. Taken from (41). 
 
Although IPSS provided the gold standard for classifying MDS, it continued to be 
updated with increasing the amount of data available. Using a much larger 
international MDS patient database, a panel of scientists provide a revised version of 
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IPSS (IPSS-R) (IPSS-R, n = 7012, IPSS, n = 816). Although bone marrow blast 
percentage, cytopenias, and cytogenetics remain the main criteria for MDS 
classification in IPSS-R, there are some modifications compared to IPSS.  The bone 
marrow blast percentage is divided into 3 subcategories by splitting the < 5% into 
two categories 0%-2%, > 2-< 5%, and putting the rest into one group > 10%. 
Cytogenetic abnormalities have been divided into 5 rather than 3 subcategories as 
mentioned above in Table 2. Cytopenias are evaluated based on their depth rather 
than their number. Furthermore, differentiating features such as age, performance, 
serum ferritin, and LDH have been considered for survival. IPSS-R divides the MDS 
patients into 5 prognostic subcategories very low, low, intermediate, high, and very 
high Table 3. 
 
Table 3: IPSS-R prognostic risk categories/scores 
Taken from (42) 
 
So the IPSS-R differs from IPSS in a number of criteria used for MDS classification 
Table 4(42).  
Taken together, there are four major systems for MDS classification the FAB, the 
WHO, the IPSS, and the IPSS-R. FAB is the oldest and IPSS-R the most up to date 
MDS classification system. Which one is the best system for MDS classification is 
not clear. Scientists around the world still use all the systems to some extent. 
However, IPSS and in recent year IPSS-R are becoming more or less the gold 
standard for MDS classification.  
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Table 4: Refinements of the IPSS-R beyond the IPSS 
Taken from (42). 
 
 
 
3.4 Molecular mechanisms of MDS 
 
Molecular mechanisms of MDS and other hematological malignancies have been 
conventionally studied through cytogenetics, and cloning and sequencing of single 
genes (43). Over the past couple of years, the molecular abnormalities of MDS 
especially mutations in several gene families have been revealed by means of 
massive parallel sequencing studies. An increasing list of mutated genes is being 
described in MDS including hematopoietic transcription factors (ETV6, CEBPA, 
RUNX1, SPI1 (PU.1)) (2-5), epigenetic regulators (ASXL1, TET2, DNMT3A, IDH1, 
IDH2, EZH2, SUZ12) (3, 6, 7) and microRNAs (8, 9), RNA splicing factors (SF3B1, 
SRSF2, U2AF1, ZRSR2) (10), cell cycle regulators (CDKN1A,TP53,BCL2, AURKA, 
AURKB, CDC20, MAD2L1, TUBG1) (10-14), members of the cohesin complex 
(STAG2, RAD21, SMC1, SMC3A) (10, 15, 16), members of other signaling pathways 
(JAK2, IRAK1, CTNNB1, NOTCH1, NPM1, SMAD7, TGFB1, NF-κB) (9, 16-20), 
proteins involved in immunological processes (TLR2, STAT3) (21, 22), and other 
factors (CBL, CALR, BCOR, BCORL1, SETBP1, GNAS, CDKN2B, Nup98, HoxD13) 
(2, 3, 10, 23-25) (Table 5). 
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Table 5: Frequently mutated genes in MDS in the literature 
Genes 
Hematopoietic Transcription factors 
ETV6 
CEBPA 
RUNX1 
SPI1(PU.1) 
Epigenetic regulators 
ASXL1 
TET2 
DNMT3A 
IDH1 
IDH2 
EZH2 
SUZ12 
MicroRNAs 
miR-21 
 
RNA Splicing factors 
SF3B1 
SRSF2 
U2AF1 
ZRSR2 
Cell Cycle regulators 
CDKN1A (p21) 
TP53 
BCL2 
AURKA 
AURKB 
CDC20 
MAD2L1 
TUBG1 
Cohesin complex 
STAG2 
RAD21 
SMC1A 
SMC3 
Signaling pathways 
JAK2 
IRAK1 
CTNNB1(β-catenin) 
NOTCH1 
NPM1 
SMAD7 
TGFB1 
NF-κB 
Immunology 
TLR2 
STAT3 
Others 
CBL 
CALR 
BCOR 
BCORL1 
SETBP1 
GNAS 
CDKN2B 
Nup98 
HoxD13 
Chromosomal aberrations 
11q amplifications, deletions within 5q, 17p, and 7q 
5q−, plus 8, −7 
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Cohesin complex components are among the genes that have been described in 
recent years to be frequently mutated in MDS. The cohesin complex is a highly 
conserved 4-subunit ring structure that encircles sister chromatids, allowing their 
cohesion, and also plays critical roles in transcriptional regulation, DNA replication, 
heterochromatin formation and post-replicative DNA repair (44). Somatic mutations 
in STAG2, a component of the cohesin complex, have been found in about 6% of 
MDS patients (45). In a recent work, Kon et al. (15) detected mutations and deletions 
involving various components of the cohesin complex (STAG2, RAD21, SMC1A, and 
SMC3) in 8% of patients with MDS, 10% of those with CMML, and 12% of those with 
AML (Figure 5). 
 
Figure 5: Recurrent cohesin mutations in MDS 
(a) Cohesin holds chromatin strands together within a ring-like structure that is composed of the four 
core components STAG, RAD21, SMC1 and SMC3. (b) Mutations in the core components of the 
cohesin complex found in myeloid malignancies (black arrowheads) and myeloid leukemia-derived 
cell lines (blue arrowheads). The amino acids in the alterations are referred to using their one-letter 
abbreviations (for example, R110* represents p.Arg110*). (c) Distribution of cohesin mutations and 
deletions showing a nearly mutually exclusive pattern among different myeloid neoplasms. Gene 
deletions are indicated by asterisks. The number of numerical chromosome abnormalities in each 
cohesin-mutated or deleted case is shown at the bottom. ND, not determined. Taken from (15). 
 
A similar mutation frequency was reported in AML patients by others (46), 
suggesting that altered cohesin function plays a role in myeloid leukemogenesis. 
Cohesin mutations have been found in other types of cancer as well. In glioblastoma, 
the function of STAG2 has been related to maintenance of euploidy via its role in the 
cohesin complex. In a screen of a large series of bladder tumors and cell lines, 
Taylor et al. found inactivating mutations (nonsense, frameshift and splicing) in 67 of 
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307 tumors (21.8%) and 6 of 47 cell lines (26). Functional assays in glioblastoma cell 
lines have linked loss of STAG2 expression to chromatid cohesion defects and 
aneuploidy (31). In a siRNA screen of 101 candidate driver genes in breast cancer 
cell lines, Mahmood et al. found eight driver genes including RAD21 that were 
amplified, overexpressed and critical for breast tumor cell proliferation or survival 
(29). In a retrospective observation study, Deb et al. examined RAD21 expression in 
652 colorectal cancers using a tissue microarray approach. The results showed that 
RAD21 expression is a novel prognostic marker, particularly in the context of KRAS 
mutations and most likely within cancers arising through chromosomal instability (30)        
. In a screen of a large series of early colorectal adenomas, a precocious step during 
colorectal tumorigenesis, Cucco et al. identified eleven mutations in the SMC1A 
cohesin subunit. They showed that chromosomal instability is induced in normal 
human fibroblasts after either transfection of the SMC1A mutations identified in early 
adenomas or wild-type SMC1A gene silencing (47). STAG2 is reported to be 
targeted by somatic aberrations in a subset (4%) of human pancreatic ductal 
adenocarcinoma (PDAs) (48). Loss of STAG2 protein expression is seen in human 
PDAs tumor tissue with complete absence of STAG2 staining in 4.3% of patients.  
STAG2 expression is disrupted in these tumors suggesting a tumor suppressor role 
for STAG2 in human PDAs (48). So, the cohesin complex members and especially 
STAG2 are mutated in different cancer entities. However, different cohesin members 
are mutated in different cancer entities and the functional consequences of cohesin 
mutations in different cancers is not quite clear and likely differ by tumor type. There 
are some reports on the role of cohesin mutations in chromosomal instability in 
cancer but results are controversial. To our knowledge, there is no report on the 
functional role of cohesin mutations in MDS especially in terms of chromosomal 
instability. Therefore, in the current work, we studied the frequency of STAG2 
mutations in MDS and the consequence of its loss of function with regard to 
chromosomal instability in vitro. 
 
3.5 Therapy 
 
Currently, MDS diagnosis includes evaluation of cytopenias and dysplasia by 
assessing peripheral blood and bone marrow morphology, bone marrow biopsy to 
assess marrow cellularity and dysplasia, fibrosis, and topography, and cytogenetics. 
Somatic mutations are increasingly evaluated in MDS by massive parallel 
sequencing and will be part of the approach to diagnosis of MDS in the future 
(Figure 6) (10). Nowadays, IPSS is the golden standard for diagnostic categorization 
and, correspondingly, for the choice of therapy. Once diagnosed as MDS, the 
therapy is decided based on whether it is low risk or high risk MDS. For low risk MDS 
which usually do not receive allogenic stem cell transplantation (alloSCT), some 
chemotherapeutic agents are currently available. These agents include 
hematopoietic growth factors, lenalidomide, and azanucleosides (5-azacitidine and 
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5-aza-2′-deoxycitidine (decitabine)). Erythroid growth factors (erythropoetin) are 
commonly used in MDS although there are few studies showing its efficacy and it 
has not been approved by FDA for treating MDS and anemia. Lenalidomide used in 
patients with lower risk MDS and del(5q) and has been shown to be quite effective. 
Most low risk MDS patients, however, are treated with 5-azacytidine and decitabine. 
In high risk MDS patients the following agents and approaches are available: 
Azanucleosides (5-azacitidine and 5-aza-2′-deoxycitidine (decitabine)), AML-like 
chemotherapy, and alloSCT. 5-azacitidine and decitabine are standard care for high 
risk MDS treatment. Response rates for both agents seem to be similar and both 
seem to improve survival but data from randomized clinical trials are available only 
for 5-azacitidine. AML-like chemotherapy might be used in younger patients that are 
candidates for alloSCT. Although usually restricted to young patients with a suitable 
donor, alloSCT is supposed to be the only curative treatment in MDS (49). There is 
an increasing amount of data available on somatic mutations in MDS. However, they 
have still not been integrated into therapeutic approaches in this disorder. 
 
Figure 6: Current and future approach to diagnosis and prognostication of 
MDS 
Taken from (10). 
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4 Materials and Methods  
4.1 Materials  
All the required substances and equipments for the Haloplex Target enrichment 
procedure are given in Table 6. The list of genes in the panel for targeted 
resequencing is given in Table 7. 
 
 
Table 6: Reagents and equipment required for Haloplex Target enrichment 
Haloplex reuired reagents company Catalog #
Agencourt AMPure XP 60 mL Kit
Beckman Coulter 
Genomics A63881
Agencourt SPRIPlate 96R - Ring Super Magnet Plate
Beckman Coulter 
Genomics A32782
DynaMag-2 magnet Life Technologies 12321D
Qubit 2.0 Fluorometer Life Technologies Q32866
Qubit assay tubes Life Technologies Q32856
Qubit® dsDNA BR Assay Kit Life Technologies Q32850
Eppendorf Research® (multi-channel) 8 channel (0.5-10) Eppendorf
Eppendorf Research® (multi-channel) 8 channel (10-100) Eppendorf
2 M acetic acid
10 M NaOH
10 mM Tris-HCl, pH 8.0
Adhesive seals for 96-well PCR plates Agilent 410186
Herculase II Fusion DNA Polymerase, 200 rxn Agilent 600677
VWR® MiniFuge VWR 93000-196
MPS1000 Mini Plate spinner Labnet International C1000
Microplate Foam Insert (2) Scientific industries 504-0235-00
6-inch Platform Scientific industries 146-6005-00
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Table 7: The gene panel for targeted resequencing 
 
 
4.2 Patient samples 
Genomic DNA (gDNA) was extracted from 90 patient samples by our collaborator at 
the University Hospital of Düsseldorf and was sent to the German Cancer Research 
center (DKFZ) in Heidelberg on dry ice. DNA concentration was measured by a 
Qubit fluorometer which showed a significant difference in comparison with 
NanoDrop (Figure 7). All further analysis steps were therefore based on Qubit 
fluorometer results. 225 ng of each sample were used for library preparation. 
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Figure 7: DNA concentrations measured by Qubit versus NanoDrop 
 
4.3 Library preparation 
We have created a list of 63 genes with recurrent mutations in MDS by literature 
search. The genes cover a broad range of biological phenomena as described in the 
introduction section. We have created a customized target enrichment kit using 
Agilent SureDesign software by following the instructions for this 63 gene panel 
covering their complete exome and some parts of the surrounding introns. Briefly, 
gDNA was digested by 16 different restriction enzymes. Then, the collection of 
digested restriction fragments was hybridized to the Haloplex probe capture library. 
After that, the hybridized DNA-Haloplex probes, containing biotin, was captured on 
streptavidin beads. Finally, the captured target regions were PCR amplified to 
produce a sequencing ready region (Figure 8). 
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Figure 8: Overall Haloplex target-enriched sequencing sample preparation 
workflow 
 
Step 1. Digest genomic DNA with restriction enzymes 
In this step, gDNA samples are digested by 16 different restriction enzymes to create 
a library of gDNA restriction fragments. 
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1) Use the Qubit dsDNA BR Assay or PicoGreen staining kit to determine the 
concentration of your gDNA samples. 
2) Prepare the DNA samples for the run. For 12-reaction runs, prepare 11 gDNA 
samples and one Enrichment Control DNA sample. 
a. In separate 0.2-mL PCR tubes, dilute 225 ng of each gDNA sample in 45 µL 
nuclease-free water, for a final DNA concentration of 5 ng/µL. Store on ice 
b. In a separate 0.2-mL PCR tube, dispense 45 µL of the supplied Enrichment 
Control DNA (ECD). Store on ice 
3) Prepare the Restriction Enzyme Master Mix strip 
 
The gDNA is digested in eight different restriction reactions, each containing two 
restriction enzymes. The 16 restriction enzymes are provided in two 8-well strip 
tubes that are distinguished by red and green color markers. Enzymes are combined 
from corresponding wells of the red- and green-marked strip tubes, along with 
restriction buffer and BSA to make eight different RE Master Mixes. Figure 9 
illustrates how to prepare the 8-well Restriction Enzyme Master Mix strip for a 12-
sample run using the steps detailed below. 
 
Figure 9: Preparation of the Restriction Enzyme Master Mix Strip for 12-sample 
run 
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a. Combine the amounts of RE Buffer and BSA Solution indicated in the table below 
in a 1.5-mL tube. Mix by vortexing briefly 
 
b. To begin preparation of the Restriction Enzyme Master Mix Strip, dispense the 
appropriate volume of the RE Buffer/BSA mixture to each well of an 8-well strip 
tube. 
 
 
c. Using a multichannel pipette, add the appropriate volume of each enzyme from 
the Green Enzyme Strip, with green marker aligned with tube A, to corresponding 
tubes A to H of the Restriction Enzyme Master Mix Strip. 
 
d. Using a multichannel pipette, add the appropriate volume of each enzyme from 
the Red Enzyme Strip, with red marker aligned with tube A, to each 
corresponding tube A to H of the same Restriction Enzyme Master Mix Strip. 
 
e. Mix by gentle vortexing and then spin briefly. 
f. Keep the Restriction Enzyme Master Mix Strip on ice until it is used in step   4. 
 
4) Aliquot the Restriction Enzyme Master Mixes to the rows of a 96-well plate to be 
used as the restriction digest reaction plate. 
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a. Align the Restriction Enzyme Master Mix Strip, prepared in step   3, along the 
vertical side of a 96-well PCR plate as shown below. 
b. Using a multichannel pipette, carefully distribute 5 µL of each RE master mix row-
wise into each well of the plate. 
 
Figure 10: Distribution of the restriction enzyme mastermix into 96-well plate 
Each row of the 96-well plate now contains 5 µL per well of the same restriction enzyme 
combination. 
 
5) Aliquot DNA samples into the 96-well Restriction Digest Reaction Plate(s). 
a. Align the DNA samples (11 gDNA samples and the ECD sample), prepared in 
step 2, along the horizontal side of the digestion reaction plate(s) as shown 
below. 
 
 
Figure 11: Distribution of the samples into the 96-well plate 
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b. Carefully distribute 5 µL of DNA samples column-wise into each well of the 
digestion reaction plate. If using a multichannel pipette, visually inspect pipette 
tips for equal volumes before dispensing. 
c. Seal the plate thoroughly with adhesive plastic film 
 
6) Carefully vortex the plate to mix the digestion reactions. 
7) Briefly spin the plate in a plate centrifuge. 
8) Place the Restriction Digest Reaction Plate in a thermal cycler and run the 
program in Table   below, using a heated lid. 
 
 
 
9) Validate the restriction digestion reaction by electrophoretic analysis of the 
Enrichment Control DNA (ECD) reactions. Keep the Restriction Digest Reaction 
Plate on ice during validation. 
a. Transfer 4 µL of each ECD digestion reaction from wells of the digestion reaction 
plate to fresh 0.2-mL PCR tubes. 
b. Incubate the removed 4-µL samples at 80°C for 5 minutes to inactivate the 
restriction enzymes. 
c. Analyze the prepared samples using gel electrophoresis as follow: 
I. Use The E-Gel® iBase™ Power System and E-Gel®4% and the corresponding 
program as shown below 
  
Figure 12: E-Gel® iBase™ Power System and E-Gel®4% and how to load 
samples 
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II. Select the corresponding program for E-Gel®4% and set the time for 30 minute 
III. Open the package and remove the gel. Gently remove the comb(s) from the gel. 
IV. Slide the cassette into the two electrode connections on the E-Gel® iBase™ 
device. Press on the left side of the cassette to secure it into the iBase™ Power 
System. The two electrodes on the right side of the gel cassette must be in 
contact with the two electrode connections on the base as shown above. The 
LED illuminates with a steady red light to show that the cassette is correctly 
inserted. 
V. Load your samples and the appropriate molecular weight markers, and add water 
to any empty wells as shown above. 
VI. To start electrophoresis press the Go button, a green light illuminates to show 
that the run is in progress. The LCD displays the countdown time while the run is 
in progress. 
VII. The run will stop automatically when the programmed time has elapsed. 
VIII. Press and release the Go button to stop the beeping. 
IX. The ECD sample contains genomic DNA mixed with an 800-bp PCR product that 
contains restriction sites for all the enzymes used in the digestion protocol. When 
analyzing validation results, the undigested control should have gDNA bands at 
>2.5 kbp and a PCR product band at 800 bp. Each of the eight digested ECD 
samples should have a smear of gDNA restriction fragments between 100 and 
2500 bp, overlaid with three predominant bands at approximately 125, 225 and 
450 bp. These three bands correspond to the 800-bp PCR product-derived 
restriction fragments, and precise sizes will differ after digestion in each of the 
eight RE master mixes. 
X. Look at the gel under UV light and it should look like the picture below 
 
 
Figure 13: Validation of restriction digestion by gel electrophoresis 
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 Lanes 1–8: ECD digestion reactions A–H, Lane 9: Undigested Enrichment Control DNA, Lane 
10: LowRanger 100 bp DNA Ladder. 
 
 
 
 
 
XI. If you do not have access to the E-Gel® iBase™ Power System and E-Gel®4% 
you can add 4 µl 6x TAE loading dye to each of the samples and load it on a 4% 
Agarose gel and run it for one hour. But you might not see the bands and smear 
as clearly as by E-Gel®4% and the run takes one hour. So I suggest using E-
Gel® iBase™ Power System and E-Gel®4% since, you will need it later on for 
library purification.  
If you do not continue to the next step, samples may be stored at –20°C for 
long-term storage. There are no more long-term stopping points until after 
the PCR amplification step. 
 
Step 2. Hybridize digested DNA to HaloPlex probes for target enrichment and 
sample indexing 
In this step, the collection of gDNA restriction fragments is hybridized to the HaloPlex 
probe capture library. The duration of the hybridization reaction is determined by the 
probe density of your design. Refer to the Certificate of Analysis provided with Box 1 
of your kit to determine the hybridization conditions appropriate for your design. 
HaloPlex probes are designed to hybridize selectively to fragments originating from 
target regions of the genome and to direct circularization of the targeted DNA 
fragments. During the hybridization process, Illumina sequencing motifs including 
index sequences are incorporated into the targeted fragments. 
1) Prepare a Hybridization Master Mix by combining the reagents in the Table 
below. Mix well by gentle vortexing, then spin the tube briefly. 
 
 
 
2) Distribute 70 µL of the Hybridization Master Mix to each of 12 0.2-mL tubes 
3) Add 10 µL of the appropriate Indexing Primer Cassette to each tube containing 
Hybridization Master Mix. 
Be sure to add only one specific Indexing Primer Cassette to each hybridization 
tube, using different indexes for each sample to be multiplexed. Record the 
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identity of the Indexing Primer Cassette added to each tube for later sequence 
analysis. 
4) Transfer digested DNA samples from the 96-well Restriction Digest Reaction 
Plate(s) directly into the hybridization reaction tubes prepared in step   3. Transfer 
all eight digestion reactions that correspond to one DNA sample into the 
appropriate hybridization reaction tube. After addition of each individual digest 
reaction to the hybridization solution, mix by pipetting before adding the next 
digest reaction to ensure complete inactivation of the enzymes. 
     For the ECD sample, add 32 µL of nuclease-free water, in addition to the digested     
DNA samples, to compensate for the volume removed for digest validation. 
After pooling, each hybridization reaction contains the following components: 
 70 µL Hybridization Master Mix 
 10 µL Indexing Primer Cassette 
 approximately 80 µL pooled digested DNA samples 
5) Vortex the mixtures briefly and then spin tubes briefly. 
6) Place the hybridization reaction tubes in a thermal cycler. Run the appropriate 
program in Table   below, using the hybridization duration listed on the Certificate 
of Analysis. Use a heated lid. Do not include a low-temperature hold step in the 
thermal cycler program. Incubation at 54°C for more than the indicated time is not 
recommended. 
 
* Thermal cyclers that use calculated temperature methods cannot be set to 160 µL 
reaction volumes. In that case, enter the maximum possible volume. 
Step 3. Capture the target DNA 
In this step, the circularized target DNA-HaloPlex probe hybrids, containing biotin, 
are captured on streptavidin beads. 
1) Remove reagents to be used in upcoming protocol steps from cold storage and 
allow the solutions to reach room temperature: 
•From –20°C storage, remove the Capture Solution, Wash Solution, Ligation Solution 
and SSC Buffer. 
•From +4°C storage, remove the HaloPlex Magnetic Beads. 
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2) Obtain or prepare 0.5 µL per sample, plus excess, of 2 M acetic acid, for use on 
page   33. 
3) Prepare 25 µL per sample, plus excess, of fresh 50 mM NaOH for use in the DNA 
elution step on page   34. Prepare the 50 mM NaOH solution from a 10M NaOH 
stock solution. 
4) Vigorously resuspend the provided HaloPlex Magnetic Beads on a vortex mixer. 
The magnetic beads settle during storage. 
5) Prepare 40 µL (1 Volume) of HaloPlex Magnetic Beads per hybridization sample, 
plus excess, for the capture reaction: 
a. Transfer the appropriate volume of bead suspension to a 1.5-mL tube. 
 
b. Put the tube into a 1.5 mL tube-compatible magnetic rack for 5 minutes. 
c. After verifying that the solution has cleared, carefully remove and discard the 
supernatant using a pipette. 
d. Add an equivalent volume of Capture Solution to the beads and resuspend by 
pipetting up and down. 
 
e. Remove the hybridization reactions from the thermal cycler and immediately add 
40 µL of the prepared bead suspension to each 160-µL hybridization reaction. 
6) Remove the hybridization reactions from the thermal cycler and immediately add 
40 µL of the prepared bead suspension to each 160-µL hybridization reaction 
7) After adding the magnetic beads, mix the capture reactions thoroughly by 
pipetting up and down 15 times using a 100-µL pipette set to 80 µL. 
8) Incubate the capture reactions at room temperature for 15 minutes. 
9) Briefly spin the tubes in a desktop centrifuge and then transfer the tubes to the 
Agencourt SPRIPlate Super Magnet magnetic plate. 
10) Wait for the solution to clear (about 30 seconds), then remove and discard the 
supernatant using a pipette set to 200 µL. 
11) Wash the bead-bound samples: 
 
a. Remove the capture reaction tubes from the magnetic plate and add 100 µL of 
Wash Solution to each tube. 
b. Resuspend the beads thoroughly by pipetting up and down 10 times using a 100-
µL multichannel pipette set to 80 µL. 
c. Incubate the tubes in a thermal cycler at 46°C for 10 minutes, using a heated lid. 
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Do not include a low-temperature hold step in the thermal cycler program following 
the 10-minute incubation. 
 
d. Briefly spin the tubes in a desktop centrifuge at room temperature and then 
transfer the tubes to the magnetic plate. 
e. Wait for the solution to clear (about 30 seconds), then carefully remove and 
discard the supernatant using a pipette set to 120 µL. If necessary, carefully 
remove any residual liquid with a 20-µL volume pipette. 
Step 4. Ligate the captured, circularized fragments 
In this step, DNA ligase is added to the capture reaction to close nicks in the 
circularized HaloPlex probe-target DNA hybrids. 
1) Prepare a DNA ligation master mix by combining the reagents in the following 
table. Mix the components thoroughly by gentle vortexing then spin the tube 
briefly. 
 
2) Add 50 µL of the DNA ligation master mix to the beads in each DNA capture 
reaction tube. 
3) Resuspend the beads thoroughly by pipetting up and down 15 times using a 100-
µL multichannel pipette set to 40 µL 
4) Incubate the tubes in a thermal cycler at 55°C for 10 minutes, using a heated lid. 
The thermal cycler may be programmed to include a 4°C hold step following the 
10-minute incubation. During the 10-minute incubation, prepare the PCR master 
mix as specified in the following step. 
Step 5. Prepare the PCR Master Mix 
In this step, you prepare a PCR master mix for the captured target DNA amplification 
step on page 35. 
1) Prepare the PCR master mix by combining the reagents in the following table. 
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2) Mix the master mix components by gentle vortexing, then distribute 30-µL 
aliquots to fresh 0.2-mL reaction tubes. 
3) Store the tubes on ice until they are used in “Step 7. PCR amplify the captured 
target libraries” on page   35. 
Step 6. Elute captured DNA with NaOH 
When the 10-minute ligation reaction period is complete, proceed with the following 
steps to elute the captured DNA libaries. 
1) Briefly spin the ligation reaction tubes in a desktop centrifuge and then transfer 
the tubes to the magnetic plate. 
2) Wait for the solution to clear (about 30 seconds), then carefully remove and 
discard the supernatant using a pipette set to 50 µL. 
3) Remove the tubes from the magnetic plate and add 100 µL of the SSC Buffer 
provided with the kit to each tube. 
4) Resuspend the beads thoroughly by pipetting up and down 10 times using a 100-
µL multichannel pipette set to 80 µL. 
5) Briefly spin the tubes and then return the tubes to the magnetic plate. 
6) Wait for the solution to clear (about 30 seconds), then carefully remove and 
discard the SSC Buffer using a multichannel pipette set to 120 µL. If necessary, 
carefully remove any residual liquid with a 20-µL volume pipette. 
7) Add 25 µL of 50 mM NaOH, which was freshly-prepared on page   29, to each 
tube. 
8) Resuspend the beads thoroughly by pipetting up and down 10 times using a 100-
µL multichannel pipette set to 15 µL. 
9) Incubate samples for 1 minute at room temperature to allow elution of the 
captured DNA. 
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10) Briefly spin the tubes and then transfer the tubes to the magnetic plate. Proceed 
immediately to PCR amplification in the following section. 
Step 7. PCR amplify the captured target libraries 
1) Prepare amplification reactions by transferring 20 µL of cleared supernatant from 
each tube on the magnetic plate to a PCR Master Mix tube held on ice (from 
page   33). 
2) Mix by gentle vortexing and then spin briefly to collect the liquid. 
3) Place the amplification reaction tubes in a thermal cycler and run the program in 
Table   below, using a heated lid. 
The optimal amplification cycle number varies for each HaloPlex Probe design. 
Consult the Certificate of Analysis (provided with HaloPlex Target Enrichment 
System Box 1) for the PCR cycling recommendation for your probe. In this case 20 
cycles. 
 
 
If you do not continue to the next step, PCR products may be stored at –20°C for up 
to 72 hours or at 8°C overnight. For best results, however, purify PCR products as 
soon as possible. 
 
Step 8. Purify the amplified target libraries 
Purification can be done either with Agencourt AMPure beads following the protocol 
or gel purification using the following protocol. In author’s experience, gel purification 
is preferred therefore it is brought below. The libraries were prepared in tow round 
each round 48 libraries. If the PCR product can be visualized on the gel, then the gel 
purification should work. In the first round some of libraries were purified with 
AMPure beads and if the adapter peak was high, the libraries were purified with gel 
purification (Figure 14 and Table 8).  
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Figure 14: Representative enriched libraries 
Libraries 1 and 2 in this figure are fine but, as you can see library 3 failed completely and 
library 4 is good but there is an adapter peak that could cause problem during sequencing 
and has to be removed 
Name Index 
Peak 
Size  
range 
indicated 
(bp) 
average 
size 
library 
MW 
Concentration 
found [ng/µl] 
volume 
final 
ng 
purified? 
MDS6 6 158-698 358 232700 3,5 20,0 70,9 yes perfect! 
MDS9 9 162-656 358 232700 2,8 20,0 56,6 yes perfect! 
MDS35 37 138-644 338 219700 5,4 20,0 107,7 yes perfect! 
MDS23 25 160-565 334 217100 4,5 20,0 89,8 yes perfect! 
MDS37 39 163-663 366 237900 7,6 20,0 152,1 yes perfect! 
MDS44 46 140-641 355 230750 6,4 20,0 128,7 yes perfect! 
MDS46 48 200-653 371 241150 2,8 20,0 56,0 yes perfect! 
MDS20 21 168-572 351 228150 28,4 20,0 568,8 yes perfect! 
MDS22 23 168-592 356 231400 22,8 20,0 456,6 yes perfect! 
MDS29 31 165-666 369 239850 28,0 20,0 560,0 yes perfect! 
MDS28 30 164-584 354 230100 18,6 20,0 372,4 yes perfect! 
 
Table 8: Gel purified libraries 
The libraries with a big adapter peak were gel purified in order to remove the peak  
 
 
In the second round, all the libraries were purified using gel purification as follow:   
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1) Spin the PCR product tubes briefly  
2) Transfer the PCR product to E-Gel®4% and run it using Gel® iBase™ Power 
System for 30 minutes 
3) Visualize the amplicons using UV light and like the Figure below: 
 
Figure 15: Sample libraries visualized under UV 
 
4) cut the gel from 200 to 600 bp as follow: 
 
Figure 16: Sample libraries visualized and cut under UV 
 
5) Purify the excised gels with Qiagen MinElute Gel Extraction Kit by following the 
protocol 
6)  Check the libraries on Agilent Bioanalyzer 2100. Representative libraries are 
brought in  
7)  
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8) Figure 14. 
9) Select the libraries with good quality for equimolar pooling  
10) Calculate the required sample amount  for 10 nmol/L equimolar pooling using the 
Average library size and the concentration  given by Bioanalyzer 2100 using 
(Table 9). 
383 bp Average Size of Library 
248950 daltons 650 daltons/bp 
0,24895 ug/pmol 10E6 daltons = 1 ug/pmol 
248,95 ng/pmol  
13,1 ng/ul Template Concentration 
0,053 pmol/ul  
0,053 nmol/ml  
52,621 nmol/L  
   
10 nmol/L Required for ~30K clusters 
   
5,26 Dilution Factor  
1,90 ul template  
8,10 EB Buffer  
10,00 Total  
   
RED User Input  
Purple Sample Prep  
 
Table 9: Template amount required for equimolar pooling 
This table is an example of the excel table used to calculate the amount of template and buffer in 
order to reach an equimolar of 10 nmol/ liter. The parts written in red are user input including Average 
library size in base pair (bp) in this case 383, template concentration ng/µl here 13.1, and the required 
equimolar concentration for ~30K clusters here 10 nmol/L. The parts written in purple are given 
results which include the amount of template and buffer.  For each library Average library size and 
template concentration in given and the amount of template and buffer in microliter will be calculated 
and appears. For pulling, the given amounts of template and buffer will be pulled together.  
 
 
The required template for equimolar pooling can be calculated using the Average 
library size and template concentration which is measured by Bioanalyzer 2100. 
 
11) Pool the libraries and check the quality on a Bioanalyzer 2100 like in Figure 17 
and Figure 18. 
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Figure 17: 31 pooled libraries 
 
Libraries were pooled together at equimolar ratio of 10 picomolar and checked for 
quality on Agilent Bioanalyzer 2100 
 
 
Figure 18: 32 pooled libraries 
 
Libraries were pooled together at equimolar ratio of 10 picomolar and checked for 
quality on Agilent Bioanalyzer 2100 
 
12) Send the pools for sequencing on an Ilumina HiSeq 2000 for paired end 100 
base pair sequencing 
 Libraries were prepared as above and sent for quality control on an Agilent 
Bioanalyzer 2100. The library pools were sent for sequencing on an Ilumina HiSeq 
2000 for paired end 100 base pair sequencing. 
4.4 Data analysis 
We received a total of 90 paired FASTQ files with removed indexes. These data 
were analyzed by established bioinformatics pipelines developed by our 
collaborators at the DKFZ. 
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4.5 Sanger sequencing  
The single nucleotide variations (SNVs) in TP53, STAG2, and AKAP9 were verified 
by Sanger sequencing as follow: 
The location of the SNVs in transcript was found in Ensemble. The gene was 
searched on Ensemble and the corresponding transcript was selected for cDNA 
sequence. The genomic sequence or, if the SNV was in one exon, the cDNA 
sequence was copied in APE plasmid software. The location of the mutation was 
found in the sequence and PCR primers were designed approximately 300 base pair 
upstream and downstream of the SNV. The list of PCR primers is brought in Table 
10. 
TP53 Mutation verification sequence 
TP53_SNVs_Fw AGGCCTCTGATTCCTCACTGATTG 
TP53_SNVs_Rev GTCAGAGGCAAGCAGAGGCT 
SA2 Mutation verification  
SA2_S1075X_Fw GTTCATGACCTTTCAGATGTCACTCCG 
SA2_S1075X_Rev tccctatgcatacagtgtagcacaga 
  
SA2_R146X_Fw CTTGTGCATACTGAGAATAGATAGCA 
SA2_R146X_Rev CCCAGCCTAATGCTTACAATTTAATAAT 
  
SA2_Y433H_Fw GTACTGTTAATATGCTTAGAATTAGGACGT 
SA2_Y433H_Rev TGTGAAAGCTTCGATATGATCTGTAGT 
  
AKAP9 mutation verification  
AKAP9_N408H_Fw ACTAGGAGAATTACAAGAACAGATTGTGC 
AKAP9_N408H_Rev CTCCATCTGTGCCATGTGTTGT 
  
  
Table 10.PCR primers for Sanger sequencing  
 
Five microliter PCR product was run on a gel. When one single band with the right 
size was observed, the PCR product was purified using The MinElute PCR 
Purification Kit from QIAGEN following the protocol. Importantly, in the first step 3 
Molar sodium acetate wit PH 5 was used as suggested in the protocol otherwise the 
product was lost. The purified PCR product was sent to GATC for sequencing. The 
sequence was blasted against the cDNA or gDNA sequence and the mismatches 
were found. The SNVs were verified by looking at the sequencing chromatograms 
and comparing them with the control.   
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4.6 Characterization of the created knockout cell lines 
4.6.1 Protein Expression by Western Blotting 
 
Western blot was done according to the established protocol in the lab. First, protein 
lysates were prepared, followed by SDS-page gel separation and finally blotting. The 
following materials were used: 
A: Preparation of protein/cell lysates 
Solutions: 
RIPA: 
 
50mM Tris-Cl pH7.4 
1% NP-40 
0.25% Sodium deoxycholate 
150 mM NaCl 
1mM EDTA 
1 complete tablet (Protease inhibitor cocktail, Roche) per 50 ml 
5 Phospho-Stop tablets (Roche) per 50 ml 
 
6xSDS-sample buffer: 
7ml 1M Tris-Cl/0,4% SDS, pH6.8 
3ml glycerol 
1g SDS 
0.93g DTT 
1,2 mg bromphenol blue 
Add VE-H2O to 10ml  
B: SDS gel electrophoresis 
Solutions and Chemicals: 
 30 % Acrylamide/Bisacrylamide 
 TEMED  
 10 % APS  
 1,5 M Tris pH 8.8 0.4 % SDS (SDS-PAGE) 
 1,0 M Tris pH 6.8 0.4 % SDS (SDS-PAGE) 
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 20 % SDS (SDS-PAGE) 
10x Running Buffer for SDS-PAGE:  
 
30.3 g   Tris 
144.1 g   Glycine 
10 g   SDS  
dissolve in 1000 ml H2O 
to obtain working solution take 100 ml 10x buffer 
Adjust volume with H2O to 1000 ml 
 
C: Western Blot 
Materials:   
 TBS supplemented with 0.1% Tween-20 (TBS-T; common container: refill when 
empty!) 
 TBS-T supplemented with 5% (w/v) dry milk (TBS-T/5% milk; prepare freshly!) 
 Membrane (PVDF or nitrocellulose) 
 Methanol (in case PVDF membranes are to be used) 
 Ponceau S working solution (usually commercial, ready-to-use, 0.1% solution) 
 Primary and secondary antibodies 
 ECL reagents 
 Films for exposure 
 
Buffers:  
20X Borate buffer  
25 g   Boric acid 
 
7.45 g EDTA 
 
Dissolve in 1000 ml H2O pH 8.8 (adjust with NaOH: about 30 pellets) 
Dilute 1:20 to obtain working solution (1x Borate Buffer) 
 
 
Antibodies: 
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The following antibodies were used: RAD21 (D213) Antibody (Cell Signaling 
Technologies 4321), SA-2 Antibody (J-12) (Santa Cruz Biotechnologies sc-81852). 
The antibodies were diluted according to the company recommendations. 
 
4.6.2  Protein Expression by Immunofluorescence 
In this procedure the cells were first cultured on coverslips and after reaching 
confluency the cells were fixed and stained as follows: 
Fixation Methods: 
1) Methanol: 
Carefully add 100% methanol (cold, stored at -20°C) to the coverslips, they should 
be covered by methanol incubate for 10 min at room temperature dry coverslips on 
filter paper fixed coverslips can be stored at -20°C 
2) Methanol/Acetone: 
Add methanol/acetone-mixture (1:1, cold, stored at -20°C) to the coverslips, they 
should be covered by methanol/acentone incubate for 7 min at room temperature dry 
coverslips on filter paper fixed coverslips can be stored at -20°C 
3) 4% PFA: 
Carefully add 4% PFA/PBS to the coverslips, they should be covered incubate for 15 
minutes at room temperature wash coverslips twice with 1xPBS fixed coverslips, 
covered by 1xPBS, can be stored at 4°C for up to two weeks permeabilise cells prior 
to immunofluorescence staining add PBS/0,2%Triton-X-100 to coverslips incubate 
for 5min at room temperature wash coverslips twice with 1xPBS 
4) PHEM-Extraction: 
Using this method you extract cytosolic components prior to fixation (reduced 
cytosolic background) 
1xPHEM-buffer: 60mM PIPES, 25mM HEPES, 8mM EGTA, 2mM MgCl2, pH = 6.9 
Carefully add PHEM-buffer supplemented with 0.5%TritonX-100 to the coverslips, 
they should be covered incubate for up to  5 minute depending on the cells at room 
temperature wash coverslips once with PHEM-buffer without TritonX-100, they 
should be covered fix cells with one of described fixation methods above 
Immunofluorescence staining: 
The cells are extracted by PHEM if necessary and fixed using one of the above 
methods. Staining was done according to the established protocol in the lab. 
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4.7 Crisper/Cas9 knock out  
We used Crisper/Cas9 technology in order to knock out STAG2. Cas9 is a nuclease  
guided by small RNAs (sgRNA) through Watson-Crick base pairing with target DNA 
(Figure 19) (33). SgRNA consists of a 20-nucleotide guide sequence and a scaffold. 
The guide sequence recognizes the target cleavage sites through protospacer 
adjacent motif (PAM) which is a 5´-NGG-3´ motif and binds directly upstream of it 
and Cas9 mediates a double strand cleavage 3 bp upstream of PAM sequence. 
 
Figure 19: Schematic of the RNA-guided Cas9 nuclease  
The Cas9 nuclease from S. pyogenes (in yellow) is targeted to genomic DNA (shown as example is 
the human EMX1locus) by an sgRNA consisting of a 20-nt guide sequence (blue) and a scaffold 
(red). The guide sequence pairs with the DNA target (blue bar on top strand), directly upstream of a 
requisite 5′-NGG adjacent motif (PAM; pink). Cas9 mediates a DSB ~3 bp upstream of the PAM (red 
triangle). Adapted from (33). 
 
Cas9 promotes genome editing by stimulating a DSB at a target genomic locus. 
Upon cleavage by Cas9, the target locus typically undergoes one of two major 
pathways for DNA damage repair (Figure 20): the error-prone nonhomologous end 
joining (NHEJ) or the high-fidelity homology-directed repair (HDR) pathway, both of 
which can be used to achieve a desired editing outcome. In the absence of a repair 
template, DSBs are re-ligated through the NHEJ process, which leaves scars in the 
form of insertion/deletion (indel) mutations. NHEJ can be harnessed to mediate gene 
knockouts, as indels occurring within a coding exon can lead to frameshift mutations 
and premature stop codons (33). 
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Figure 20: DSB repair promotes gene editing 
DSBs induced by Cas9 (yellow) can be repaired in one of two ways. In the error-prone NHEJ 
pathway, the ends of a DSB are processed by endogenous DNA repair machinery and rejoined, 
which can result in random indel mutations at the site of junction. Indel mutations occurring within the 
coding region of a gene can result in frameshifts and the creation of a premature stop codon, resulting 
in gene knockout. Alternatively, a repair template in the form of a plasmid or  a single stranded 
oligodeoxy nucleotide  (ssODN) can be supplied to leverage the HDR pathway, which allows high 
fidelity and precise editing. Single-stranded nicks to the DNA can also induce HDR. Adapted from 
(33). 
 
Here, we describe considerations for designing the 20-nt guide sequence, protocols 
for rapid construction and finally the use of the Cas9 nuclease to mediate NHEJ-
based genome modifications in the HCT116-p53+/+ and HCT116-p53-/- cell lines 
(Figure 21). 
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Figure 21: Creating knockout cell lines - timeline and overview 
Steps for reagent design, construction, validation and cell line expansion are depicted. Custom 
sgRNAs (light blue bars) for each target, as well as genotyping primers, are designed in silico via the 
CRISPR Design Tool (http://tools.genomeengineering.org). sgRNA guide sequences can be cloned 
into an expression plasmid bearing both sgRNA scaffold backbone (BB) and Cas9, pSpCas9 (BB). 
The resulting plasmid is annotated as pSpCas9 (sgRNA). Completed and sequence-verified pSpCas9 
(sgRNA) plasmids and optional repair templates for facilitating HDR are then transfected into cells 
and assayed for their ability to mediate targeted cleavage. Finally, transfected cells can be clonally 
expanded to derive isogenic cell lines with defined mutations. Adapted from (33). 
 
Protocol: taken and modified from reference 33. 
A: Design of targeting components and the use of the crispr Design tool 
1. Input target genomic DNA sequence. An online CRISPR Design Tool 
(http://tools.genome-engineering.org) is provided that takes an input sequence (for 
example, a 1-kb genomic fragment from the region of interest), identifies and ranks 
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suitable target sites and computationally predicts off-target sites for each intended 
target. Alternatively, one can manually select guide sequences by identifying the 20-
bp sequence directly upstream of any 5′-NGG. 
2. Order necessary oligos and primers as specified by the online tool. If the cleavage 
site is chosen manually, the oligos or primers should be designed as described in 
Figure 22. 
 
Figure 22. Cloning strategy  
The guide oligos for the top strand example (blue) contain overhangs for ligation into the pair of BbsI 
sites in pSpCas9(BB), with the top and bottom strand orientations matching those of the genomic 
target (i.e., the top oligo is the 20-bp sequence preceding 5′-NGG in genomic DNA). Digestion of 
pSpCas9(BB) with BbsI allows the replacement of the Type II restriction sites (blue outline) with direct 
insertion of annealed oligos. Likewise, a G-C base pair (gray rectangle) is added at the 5′end of the 
guide sequence for U6 transcription, which does not adversely affect targeting efficiency. Alternate 
versions of pSpCas9(BB) also contain markers such as GFP or a puromycin resistance gene to aid 
the selection of transfected cells. Adapted from (33). 
 
B: Cloning sgrna into the pspcas9(BB) vector for co-expression with cas9 
NOTE: 
Due to the simultaneous digestion-ligation step, the guide oligos CANNOT contain 
any BbsI enzyme site (i.e. the nucleotide sequence ‘GAAGAC’ or ‘GTCTTC’).  
1. Phosphorylate and anneal each pair of oligos: 
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1 ul  oligo 1 (100µM) 
1 ul  oligo 2 (100µM) 
1 ul  10X T4 Ligation 
Buffer (NEB) 
6.5 ul  ddH2O 
0.5 ul  T4 PNK (NEB)  
10 ul  total 
Anneal in a thermocycler using the following parameters: 
37 °C 30 min 
95°C  5 min and then ramp down to 25°C  at 5°C  /min 
Dilute the annealed oligo 1:250 (250-fold). 
2. Set up digestion-ligation reaction: 
X ul  pX330 or other backbone vector (100ng) 
2 ul  phosphorylated and annealed oligo duplex from step 1 (1:250 dilution) 
2 ul  10X Tango buffer (or FastDigest Buffer) 
1 ul  DTT (10mM to a final concentration of 1mM) 
1 ul  ATP (10mM to a final concentration of 1mM) 
1 ul  FastDigest BbsI (Thermo Fisher Fermentas) 
0.5 ul  T7 DNA ligase 
Y ul  ddH2O    
20 ul  total 
 
Incubate the ligation reaction in a thermocycler: 
37°C 5 min 
23°C 5 min Cycle the previous two steps for 6 cycles (total run time 1h) 
4°C hold until ready to proceed 
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3. Treat ligation reaction with PlasmidSafe exonuclease to prevent unwanted 
recombination products: 
11 ul  ligation reaction from step 4 
1.5 ul  10X PlasmidSafe Buffer 
1.5 ul  10mM ATP 
1 ul  PlasmidSafe exonuclease 
15 ul  total 
Incubate reaction at 37°C for 30 min 
 
4. Transformation with 1-2 ul of the final product into competent cells 
5. Pick colony and sequence verify the clones. 
Transfecting the sequence verified plasmid into target cells  
1. Seed the cells 24 hours before transfection in 6 well plates 
 2. Seed enough plates and Check if the confluency is above 50% 
3. Choose the best wells for transfection  
4. Lable  8 eppendorf tubes with  1A-4A and 1B-4B respectively 
5.  Add  corresponding µl  serum Free and Antiboiotic free Optimem to tubes labelled 
1A-4A 
6. Add corresponding µl Fugene directly to Optimem in tubes 1A-4A and mix breifly 
by inverting 2 times 
7.  Add corresponding µl Plasmid DNA to tubes 1B-4B 
8. Incubate for 5 min at RT 
9. Dropwise add Optimem:Fugene mix in Tube A to the Plasmid DNA in tube B  and 
mix briefly by inverting 2 times 
10. Incubate the mixture for 15 min 
11.  Dropwise add 100 µl of the mix to each well containing 2000 µl media mix gently 
12. Incubate and check after 24 or 48 hours 
 
 
 
Puromycin selection for creating single cell colonies 
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1. After transfecting the cells for 48 hours split the cells from one 6 well plate into 10 
centimeter plates as follow 
2. Trypsinize the cells and add 10 ml medium to each 6 well plate 
3. Add respectively 4 ml , 3 ml, 2 ml, and 1 ml of the cell suspension to four 10 cm 
plates 
4. Cultivate the cells without Puromycin for 48 hours  
5. Add 0.5 µg/ml Puromycin to the HCT116 cells  
6. Change the media every 3 to 4 days in order to remove dead cells 
7. Look for single colonies to appear after about 2 weeks 
8. Pick up the single colonies and check for STAG2 expression by western blot and 
Immunofluorescence 
9. Expand and freeze down the knockout clones for further experiments   
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5 Results 
 
5.1 Somatic single nucleotides variations (SNVs) 
In order to assess the SNVs present in 63 genes that are reported to be frequently 
mutated in MDS and AML, we used a custom target enrichment approach. Oligos 
were designed against the exome and parts of surrounding introns of these 63 genes 
using Agilent SureDesign custom design software. Target regions were enriched 
through library preparation steps as detailed in the material method section. Libraries 
were pooled together and sequenced on Ilumina Highseq 2000 using a 100 bp 
paired end sequencing assay. A total of 90 paired raw reads were produced which 
were analyzed using established pipelines at the DKFZ core facility. After 
bioinformatics analysis, an excel spreadsheet was produced containing the 
chromosome coordinates, sample IDs, mutated genes, amino acid changes, 
Ensemble transcript changes, variant allele frequencies, whether or not the mutation 
has been described in the Catalog of Somatic Mutations in Cancer (COSMIC) and 
dbSNPs. To find the somatic single nucleotide variations (SNVs), all the mutations 
with dbSNPs were excluded. The data analysis was done by Ivo Buchhalter from the 
department of computational oncology. The SNVs with variant allele frequency of 
less than 20 percent were excluded. By applying the above mentioned filters, a final 
list of samples with SNVs was produced. An excel sheet was produced containing 
the patients IDs on the top horizontal side, gene IDs at the right side and karyotypes 
on the bottom side. 21 out of 90 patients showed no mutation or mutation with allele 
frequency below 20%, which were considered not mutated. These patients are 
brought at the horizontal top left side of the table and the patients IDs are written in 
red. Surprisingly, all these non-mutated patients had aberrant karyotypes as shown 
on the right side of the table. 34 genes out of 63 including SMAD7, TUBG1, ZRSR2, 
STAT3, SMC1A, SMC3, SPERT, SPI1, NPM1, NRAS, RAD21, LATS1,MAD2L1, MAP2K3, 
NFKB1, HAUS7, HOXD13, IDH1, IDH2, IRAK1, FANCD2, FOXP1, GNAS, ETV6,CDKN2B, 
CEBPA,CTNNB1, CDC20, C19orf80, CALR, AURKA, AURKB, B3GALT6, BCL2, and 
AGBL1 showed no mutation. 4 genes including TET2, SRSF2, SETBP1, and HAUS3 
were mutated only in patients with normal karyotype. BCOR, BCORL1, CBL, 
NOTCH1, SF3B1, and TGFB1 were mutated in both patients with normal and 
abnormal karyotypes. DNMT3A, NIPBL, BUB1B, RUNX1, EZH2, SUZ12, FANCA, 
JAK2, ASXL1, CDKN1A, AKAP9, STAG2, and TP53 were exclusively mutated in 
patients with abnormal karyotype. TP53 was most frequently mutated in the patients 
with abnormal karyotypes and after that STAG2, AKAP9 and CDKN1A (Table 11). 
Interestingly, all these four genes are related to chromosomal instability. The 
mutations in TP53, STAG2 and AKAP9 were verified by Sanger sequencing.  
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Table 11: Mutational analysis of 90 MDS patient bone marrow and blood 
samples 
The mutational status of 29 genes in 90 MDS samples together with their karyotypes is shown. Filled 
boxes show SNVs. The patient IDs written in red, harbor no mutation.  
 
5.2 Mutation verification 
SNVs were found in the gene sequence in the Ensemble database. The 
corresponding sequence containing the SNV was copied to Ape plasmid software. 
After marking the SNV, PCR primers were designed manually at 300 bp upstream 
and downstream of the SNV. The target region was PCR amplified and ran on an 
agarose gel. If a single band was observed, the PCR product was purified using the 
Minelute PCR purification kit following the protocol. The purified PCR product was 
sent to GATC for sequencing. The result was visualized in Ape plasmid software. 
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Three SNVs in TP53, one SNV in STAG2, and one SNV in AKAP9 were verified by 
PCR followed by Sanger sequencing.  
TP53 
Three SNVs in TP53 were verified by Sanger sequencing. In MDS patients 76 and 
79, cysteine 238 (C) was exchanged with tyrosine (Y) and in MDS patient 51 valine 
216 (V) was replaced by methionine (M) (Figure 23). HCT116 WT serves as a 
negative control. 
 
Figure 23: The SNVs in TP53 verified by Sanger sequencing 
SNVs can be observed in MDS samples in comparison with the HCT116 control cell line. The sample, 
gene and the corresponding base and amino acid change is brought at the top of each 
chromatogram. cysteine (C), tyrosine (Y), methionine (M), valine (V).  
 
STAG2 
In total, four out of 90 samples had a SNV in STAG2. Arginine 146 (R) and serine 
1075 (S) were replaced by a stop codon and tyrosine 433 (Y) was exchanged with 
histidine (H). Due to lack of material only one of the three SNVs was verified by 
Sanger sequencing (Figure 24). HCT116 WT serves as a negative control. 
 57 
 
Figure 24: Somatic SNVs found in STAG2 
Arginine 146 (R) and serine 1075 (S) were replaced by a stop codon and tyrosine 433 (Y) was 
exchanged with histidine (H). Only serine replacement was verified by Sanger sequencing due to 
material availability.  
 
AKAP9 
In total, 3 out of 90 samples were mutated in AKAP9. Due to lack of material only 
one of the SNVs was verified by Sanger sequencing (Figure 25). HCT116 WT 
serves as a negative control. 
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Figure 25: Somatic SNVs found in AKAP9 
Only one SNV was verified by Sanger sequencing due to material availability. Asparagine 408 (N) 
was replaced by histidine (H), leucine 705 (L) with valine (V), and isoleucine 826 (I) with methionine 
(M).  
 
5.3 STAG2 expression in AML 
STAG2 has been reported to be affected by nonsense mutations leading to loss of 
protein expression in AML as well. Therefore, we used immunofluorescence staining 
and Western blotting in order to assay STAG2 expression in AML. For immuno-
fluorescence staining the blood or bone marrow mononuclear cells were brought on 
coverslips using cytospinning and were fixed with methanol and kept at -20°C till 
staining. Cell pellets were frozen at -80°C and were used for preparing protein 
lysates following the protocol given in the materials and methods section. Expression 
of STAG2 was lost in 18 out of 74 AML cases by immunofluorescence staining. 
Representative samples are shown in Figure 26A. STAG2 expression was 
measured by Western blotting as shown in Figure 26B. In both assays patient 070 
showed normal STAG2 expression and STAG2 expression was lost in patient 107. 
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Figure 26: STAG2 expression in AML 
(A) Representative images showing AML cases with normal (070) and lost (107) STAG2 expression. 
HCT116 STAG2 wildtype and knockout cells serve as positive and negative controls, respectively. (B) 
Expression analysis of STAG2 by Western blotting in wildtype HCT116 as a positive control and six 
AML cases.  
 
5.4 STAG2 mutation in AML 
In order to determine the reason for loss of STAG2 expression in AML, we used Sanger 
sequencing of the whole cDNA to identify mutations that could be responsible for STAG2 
loss of expression. PCR primers were designed in a way that produced four amplicons 
covering the whole STAG2 cDNA. These four amplicons were PCR amplified separately and 
sequenced by Sanger sequencing. The results were blasted against STAG2 cDNA in order 
to find mutations. In total 18 out of 74 samples showed loss of STAG2 expression. Cell 
pellets were available for 10 out of these 18 samples. RNA was extracted using Qiagen 
RNeasy Mini Kit from these 10 samples and cDNA was generated using Roche Transcriptor 
High Fidelity cDNA Synthesis Kit. PCR was done using CloneAmp™ HiFi PCR Premix 
following the protocol but the annealing temperature was changed to 58°C. The PCR 
product was purified using QIAGEN MinElute PCR Purification Kit and sent for sequencing 
to the GATC Company. The results were visualized in ApE plasmid software. Two out of 10 
samples showed a mutation. Patient 148 harbored cysteine 769 to stop codon mutation and 
patient 277 harbored lysine 128 to threonine mutation (Figure 27). 
A 
B 
 60 
 
Figure 27: STAG2 mutations in two AML samples 
Mutations in 277 and 148 patient samples are shown. K (lysine), T (threonine), C (cysteine), X (stop 
codon). 
 
5.5 STAG2 promoter methylation in AML 
We speculated that in patients that showed no mutation STAG2 loss of expression 
could be due to promoter methylation. Therefore, we planned to analyze the above 
mentioned 10 samples for promoter methylation. Only 7 out of 10 were analyzed due 
to material availability. The promoter region of STAG2 was identified by searching for 
STAG2 genomic sequence in the UCSC genome browser. 1000 base pairs 
upstream of the first coding exon were chosen as promoter region. This sequence 
was pasted in the online Meth Primer software (http://www.urogene.org/cgi-
bin/methprimer/methprimer.cgi ) for designing primers. PCR was done using the 
Qiagen PyroMark PCR Kit following the protocol. PCR product was purified using 
QIAGEN MinElute PCR Purification Kit and sent for sequencing to GATC. The 
STAG2 promoter was found methylated in 4 out of the 7 AML samples analysed 
(Figure 28). 
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Figure 28: Promoter methylation in 7 AML patients 
The same part of the STAG2 promoter with three CpG islands is shown. HCT116 serves as a control 
since STAG2 is highly expressed in that. The patients with blue C peak (arrow) show methylated 
promoter (samples 295PB, 295 BM, 258, 070PB). The patients without C peak in the CpG island have 
unmethylated promoter in which C is converted to T after bisulfite treatment (samples 227, 37BM, 
279).  
 
5.6 CRISPR/Cas9-based knockout 
In order to understand the consequences of STAG2 loss of expression, we used 
CRISPR/Cas9 to knock out STAG2 in HCT116 cells. The detailed procedure is 
described in the materials and methods section. For CRISPR/Cas9-based knockout 
of STAG2, we have designed two sgRNAs using an online design tool from the 
Zhang laboratory (http://crispr.mit.edu/). The oligos were synthesized, annealed and 
cloned into the Psp-Cas9-Puro vector (Addgene PX459) following the protocol 
guidelines (http://www.genome-engineering.org/ crispr/?page_id=23). Cloned oligos 
were verified by restriction digestion and Sanger sequencing. The HCT116-p53+/+ 
and HCT116-p53-/- cell lines were authenticated and characterized for expression of 
RAD21, STAG2 and p53 ( 
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Figure 29). 
 
Figure 29: Characterization of hTERT-RPE, HCT116-p53+/+ and HCT116-p53-/- 
cell lines 
Characterization of HCT116-p53
+/+
 (p53 wild type), and HCT116-p53
-/-
 (p53 null) cell lines with 
Western Blotting (left panel) and immunofluorescence staining (right panel) using indicated 
antibodies. 
 
The HCT116-p53+/+ and HCT116-p53-/- cell lines were transfected with the pSpCas9(BB)-2A-
Puro (PX459) containing STAG2 sgRNAs and selected for single clones using puromycin for 
about one month. Single clones were picked and assayed for the expression of STAG2 
using Western blotting and immunofluorescence staining. Four clonal cell lines were created 
using CRISPR/Cas9 knockout of STAG2 (Figure 30). K48 and K72 clones were created 
from the HCT116-p53+/+ cell line and K17 and K51 from the HCT116-p53-/- cell line. The 
expression of STAG2 was completely lost in clones K48, K72, and K51. In K17, however, 
only one band of STAG2 expression was lost as shown by Western blotting. The Western 
blot and immunofluorescence staining for verifying the created clones was done by Annik 
Rossberg. 
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Figure 30: CRISPR/Cas9 knockout of STAG2  
Created knockout cell lines characterized by Western blotting and immunofluorescence staining. 
HCT116-p53
+/+ 
and HCT116-p53
-/- 
cell lines were transfected with pSpCas9(BB)-2A-Puro (PX459) 
containing STAG2 sgRNAs. After 2 days of transfection, the cells were passaged in media without 
Puromycin for 48 hours. Then, puromycin was added to media and the media were changed every 4 
to 5 days. Puromycin selection was continued for about 4 weeks until single colonies appeared. The 
single colonies were picked and expanded and used for immunofluorescence staining and Western 
blotting to analyse for STAG2 expression. 
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5.7 Array-CGH of HCT116 STAG2 wildtype versus knockout clones 
In order to compare the created clones in terms of copy number variation and ploidy, 
array CGH assays were performed. HCT116-p53+/+STAG2+/+ was compared with 
HCT116-p53+/+STAG2-/- and HCT116-p53-/-STAG2+/+ was compared to HCT116-p53-/-
STAG2-/-. No major differences were detected between the karyotypes of the compared 
clones (Figure 31). The array-CGH was done by Mutlu Kartal-Kaess and Anna Jauch. 
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Figure 31: Array-CGH of HCT116 STAG2 wildtype versus STAG2 knockout 
clones 
Array-CGH was used to compare the karyotypes of HCT116 STAG2 wildtype with STAG2 knockout 
clones in TP53 wildtype and knockout backgrounds, respectively. 
 
5.8 Telomeric associations in STAG2 knockout clones  
We also used multicolor fluorescence in situ hybridization (M-FISH) in order to 
analyse for karyotypic aberrations of the created cell lines. There were no 
differences between HCT116-p53+/+STAG2+/+ and HCT116-p53+/+STAG2-/- (Figure 32). 
However, telomeric associations (tas) were observed between acrocentric chromosomes 22 
and chromosomes 13 or 15 ((tas(13;22) and tas(15;22)) in HCT116-p53-/-STAG2-/- but not 
HCT116-p53-/-STAG2+/+ (Figure 33). Tas is considered an early sign for chromosomal 
instability. The M-FISH was done by Mutlu Kartal-Kaess and Anna Jauch. 
 
 
 
Figure 32: HCT116 STAG2 wildtype and knockout clones in a TP53 wildtype 
background 
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Figure 33: Telomeric association in HCT116-p53-/-STAG2-/- cells  
Tas(13;22) and tas(15;22) was observed in HCT116-p53
-/-
STAG2
-/-
 (KO51) but not in HCT116-p53
-/-
STAG2
+/+
 (KO) cells 
 
 
5.9 Gene expression profiling of HCT116 STAG2 wildtype versus STAG2 
knockout clones 
We used gene expression profiling in order to assess whether there is a difference 
between HCT116 STAG2 wildtype versus knockout cells in terms of gene 
expression. The results showed only mild differences between STAG2 knockout and 
STAG2 wildtype clones (Figure 34). The top 20 different genes in terms of gene 
expression fold change did not belong to any known signaling pathway (Table 12). 
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Figure 34: Gene expression profiling of HCT116 STAG2 wildtype and STAG2 
knockout clones 
The following clones were compared: HCT116-p53
+/+
STAG2
+/+ 
(WT) with HCT116-p53
+/+
STAG2
-/-
 
(K48) and HCT116-p53
-/-
STAG2
-/-
 (KO51) with HCT116-p53
-/-
STAG2
+/+
 (KO). Mild differences can be 
observed between the compared clones. 
 
Table 12: The top 20 genes in terms of gene expression fold change 
HCT116-p53
+/+
STAG2
+/+ 
(WT) versus HCT116-p53
+/+
STAG2
-/-
 (K48) and HCT116-p53
-/-
STAG2
-/-
 
(KO51) with HCT116-p53
-/-
STAG2
+/+
 (KO) are respectively compared.  
 
5.10 Cell proliferation of HCT116 STAG2 wildtype versus knockout clones  
In order to compare cell proliferation rates, 500,000 cells were seeded in triplicates in 
6-well plates and were counted every 24 hours for 7 days in culture. HCT116 STAG2 
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knockout clones proliferated slower than their corresponding wildtype clones both in 
a TP53 wildtype and knockout background (Figure 35). 
 
Figure 35: comparison of proliferation rate in STAG2 knockout vs. wildtype  
HCT116-p53
+/+
STAG2
+/+
 (WT) proliferate slightly faster than HCT116-p53
+/+
STAG2
-/-
 (K48) and 
HCT116-p53
+/+
STAG2
-/-
 (K72). HCT116-p53
-/-
 STAG2
-/-
 (KO51) proliferate slightly slower than 
HCT116-p53
-/-
STAG2
+/+
 (KO). 
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6 Discussion 
 
6.1 STAG2 is the only cohesin complex component found to be mutated in 
MDS 
 
Current improvements in next generation sequencing have detected mutations in 
genes involved in a broad range of biological phenomena in different cancer entities. 
These findings include mutations in the genes encoding for the members of the 
cohesin complex (STAG2, RAD21, SMC1A, SMC3) which have been described for 
the first time in 2013 to be mutated in myeloid neoplasms suggesting a role for the 
cohesin complex in leukemogenesis (15). Recurrent mutations and deletions 
involving multiple components of the cohesin complex, including STAG2 (5.8%), 
RAD21 (0.9%), SMC1A (0.0%) and SMC3 (1.3%), were reported in MDS. These 
mutations and deletions were mostly mutually exclusive and overall occurred in 
12.1% of AML and 8.0% of MDS cases. Cohesin is composed of the four core 
subunits STAG2, RAD21, SMC1A, and SMC3 which form a ring-like structure. The 
cohesin complex has many roles including cohesion of sister chromatids, DNA 
repair, control of gene expression, chromosome segregation, DNA damage repair, 
DNA replication, and the control of heterochromatin and centromere formation (50). 
In the current work we investigated the mutational spectrum of cohesin complex 
components in MDS and if these mutations are associated with karyotype 
aberrations. Using a targeted resequencing approach we studied the occurrence of 
somatic SNVs in 90 MDS patients. We found SNVs only in STAG2 in 4 out of 90 
(4.4%) patients. The bone marrow mononuclear cells of all four patients harbored 
karyotype abnormalities. The SNVs were confirmed by Sanger sequencing. In 
contrast to previous studies, we found no mutations in other members of the cohesin 
complex. We also found somatic SNVs in TP53 in 7 out of 90 (7.8%) MDS patients. 
The SNVs in TP53 were mainly associated with complex karyotype aberrations, 
which is in accordance with previous studies. AKAP9, a centrosomal protein 
potentially involved in mitotic spindle formation and chromosome segregation, was 
also mutated in 3 out of 90 (3.3%) patients with aberrant karyotypes. Whether 
cohesin mutations are driver mutations remains unclear. Mossner and colleagues 
demonstrated on a patient-individual basis that mutations affecting epigenetic 
modifiers (eg, TET2, ASXL1) and RNA splicing factors (eg, SF3B1, SRSF2) are 
predominantly “founder” events in MDS and genes involved in signaling cascades 
(eg, JAK2 and CBL), transcription factors (eg, RUNX1 and ETV6), and cytogenetic 
lesions (eg, monosomy 7, trisomy 8, and del(5q)) are almost exclusively acquired as 
late events in MDS, emphasizing their potential use as indicators of disease 
progression (51). Their data therefore suggest that STAG2 mutations are late events 
in MDS pathogenesis, although, to our knowledge no studies have specifically 
examined the timing of the occurrence of cohesin mutations in a hierarchical manner 
in any cancer entity. Clinical outcome associated with cohesin mutations in MDS has 
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not been studied so far in detail. Data by Montalban-Bravo et al. suggest that STAG2 
mutations are an independent prognostic factor in MDS(52). According to their 
findings, the presence of STAG2 mutations is associated with decreased overall 
survival in MDS, particularly in those cases classified as lower-risk MDS by IPSS. In 
AML however, according to Thol and colleagues overall survival, relapse-free 
survival, and complete remission rates are not influenced by the presence of cohesin 
mutations (16). They found that the majority of patients with cohesin gene mutations 
had intermediate risk cytogenetics. Thol and colleagues found a strong correlation 
between cohesin mutations and NPM1 mutations in AML. STAG2 is reported to be 
mutated in 15.6% (12/77) of bladder cancer patients and its loss of function is 
associated with better prognosis (27). One of the pitfalls of our study is that we have 
not performed a correlative analysis between clinical outcomes and STAG2 
mutational status. 
 
6.2 STAG2 expression is lost in AML 
As mentioned above cohesin complex components are mutated in myeloid 
malignancies including AML. Here we investigated the protein expression of STAG2 
in 74 AML samples. STAG2 expression was lost in 24.3% of AML samples. STAG2 
expression is lost in other types of cancer as well. Solomon and colleagues observed 
complete loss of STAG2 expression in 3 out of 21 glioblastomas, 5 out of 9 Ewing 
sarcomas, and 1 out of 10 melanoma cell lines (31). We then investigated whether 
the AML samples that lost STAG2 expression harbor any mutation. For that, we 
sequenced the entire cDNA of the corresponding samples using Sanger sequencing. 
Due to sample availability we could only sequence 10 samples. Two out of 10 
samples (20%) harbored mutations. This shows that STAG2 loss is only in part due 
to STAG2 mutations. Kon and colleagues observed severely reduced expression of 
one or more cohesin components in KG-1 (STAG2) and MOLM-13 (STAG1, STAG2, 
RAD21 and NIPBL) cells without any accompanying mutations in the respective 
genes (15). They found no significant differences in protein expression of the 
cohesin components in cohesin-mutated and non-mutated cell lines in whole-cell 
extracts. However, they found that the expression of one or more cohesin 
components, including SMC1, SMC3, RAD21 and STAG2, was significantly reduced 
in the chromatin-bound fractions of cell lines with mutated or reduced expression of 
cohesin components compared with the cell lines with no known cohesin mutations 
or abnormal cohesin expression, suggesting a substantial loss of cohesin-bound 
sites on chromatin.  We speculated that STAG2 loss might be due to promoter 
methylation. In 7 out of 12 (58.3%) samples the STAG2 promoter was methylated 
which shows that loss of STAG2 expression is in part due to promoter methylation. 
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6.3 STAG2 knockout is associated with TAS in a TP53 null background 
Only few studies have investigated the role of cohesin mutations with regard to the 
induction of chromosomal instability in cancer. Some studies suggest that cohesin 
mutations are associated with chromosomal instability in some cancer types. 
Solomon et al. observed that targeted inactivation of STAG2 led to sister chromatid 
cohesion defects and aneuploidy, whereas in two aneuploid human glioblastoma cell 
lines, targeted correction of the endogenous mutant alleles of STAG2 led to 
enhanced chromosomal stability (31). To the contrary, others have shown that 
cohesin mutations are not associated with chromosomal instability. Balbas-Martinez 
and coworkers observed a loss of STAG2 expression in chromosomally stable 
tumors; STAG2 knockdown in bladder cancer cells did not increase aneuploidy (27). 
Therefore, whether cohesin mutations are associated with chromosomal instability or 
not remains controversial.  To our knowledge, whether cohesin mutations are 
associated with chromosomal instability in MDS and AML has not been investigated 
so far. We are the first to study the role of STAG2 with regard to chromosomal 
instability in myeloid malignancies. To do this, we used a Crispr/Cas9 genome 
editing approach to knockout STAG2 in HCT116-p53+/+ and HCT116-p53-/- cells. 
Although array-CGH showed no differences between STAG2 wildtype and STAG2 
knockout karyotypes, M-FISH analysis revealed telomeric associations between 
acrocentric chromosomes (tas(13;22) and tas(15;22)) to specifically occur in STAG2 
knockout cells in a TP53 knockout background. Telomeric associations have been 
reported to be precursor leasion that subsequently develop into additional 
chromosomal aberrations (53). Gelot and colleagues observed that at the genome 
level ablation of RAD21 or sororin produces large chromosomal rearrangements 
(translocation, duplication, deletion) (54), which is in part in accordance with our 
observation of TAS although in our case TAS occurred only after STAG2 knockout in 
a TP53 null background. Tirode and colleagues observed in 299 Ewing sarcoma 
patients that the concurrent occurrence of STAG2 and TP53 mutations is associated 
with a poor prognosis (55). 
 
6.4 Gene expression profiling differences between STAG2 wildtype and 
knockout clones 
 
STAG2 has been reported to be involved in the regulation of gene expression. We 
investigated whether the loss of STAG2 results in changes in gene expression. We 
observed mild differences between STAG2 wildtype and STAG2 knockout clones. 
The top 20 genes with different expression did not belong to any known signaling 
pathway. To explore whether STAG2 regulates transcription in human cancer cells, 
Solomon and colleagues used expression microarrays to measure global gene 
expression profiles of isogenic STAG2-proficient and STAG2-knockout cells. 
Expression profiles of STAG2-proficient and -deficient cells were remarkably similar 
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[i.e., only 16 of 28,869 genes (0.06%) were modulated >1.5-fold in STAG2-proficient 
42MGBA cells], which indicated that STAG2 is not likely to be a major regulator of 
global gene expression (31). However, Thota et al. observed a reduction in the 
expression of NRAS, JAK1, CBL, and HIF1A, among 28 differentially expressed 
genes, in MDS patients with reduced expression or mutation of STAG2 compared to 
patients with intact STAG2 expression (56). Additionally, data by Mullenders et al. 
showed that in vivo knockdown of cohesin complex members alters hematopoiesis 
and leads to myeloproliferative neoplasms, suggesting their role in functionally 
controlling gene expression (57). 
 
6.5 Proliferation of STAG2 wildtype and knockout clones  
We investigated the effects of STAG2 loss on proliferation of the HCT116 cell line. 
We observed no significant difference among the STAG2 null and STAG2 wildtype 
cell lines. However, the cell lines with STAG2 loss proliferated mildly slower. Kon et 
al. observed that forced expression of wild-type RAD21 and/or STAG2 induced 
significant growth suppression of the Kasumi-1 (with mutated RAD21) and MOLM-13 
(with severe reduction of RAD21 and STAG2 expression) cell lines but not the K562 
and TF1 (with wild-type RAD21) cell lines. 
7 Conclusion and perspective 
 
We found STAG2 to be mutated in 4 out of 90 (4.4%) of samples. No mutations were 
found in other members of the cohesin complex. STAG2 expression was lost in 17 
out of 74 AML samples. This was in part due to mutation and in part due to promoter 
methylation. We observed TAS in STAG2 knockout HCT116 cells in a TP53 null 
background which might be an early sign of chromosomal instability. We speculate 
that STAG2 loss at centromeres could be replaced with STAG1 which is normally 
associated with telomeres. When STAG1 is competed away from telomeres to 
centromeres, this might result in telomere instability resulting in TAS. 
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